35th Esmo Congress: Milan, Italy (fieramilanocity), 8-12 October 2010 - Press Programme Curtain Rais

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
4th October 2010, 10:02pm - Views: 429






Misc Miscellaneous European Society For Medical Oncology (ESMO) 2 image








MEDIA RELEASE PR41575



35th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press

Programme Curtain Raiser


LUGANO, Switzerland, Oct. 4 /PRNewswire-AsiaNet/ --


    Press releases will be issued during the Congress, on a daily basis.


    Please contact the ESMO Press Office at media@esmo.org if you would like

to receive the full text of the press releases/abstracts in advance,

available as of Wednesday, 6 October 2010


    R. Bastian, DE


    Surgical technique relieves painful spine fractures in patients with

metastatic cancer (embargo: 9 October, 9:00 Milan time)


    Many patients with multiple myeloma, or those whose cancer has spread

beyond the initial tumor site, suffer compression fractures in their spine. A

surgical technique appears to offer quick and effective relief for

debilitating spinal fractures often suffered by these patients.


    D. Spigel, DE


    New targeted therapy adds benefit to erlotinib in some patients with

advanced lung cancer (embargo: 9 October, 11:00 Milan time)


    A subset of lung cancer patients seem to live longer and experience

delays in disease progression when a new drug that targets a

cancer-associated molecule is added to treatment with erlotinib.


    C. Zhou, CN


    Erlotinib improves progression-free survival as first-line therapy in

advanced lung cancer: Phase-III data (embargo: 9 October, 11:00 Milan time)


    For patients with advanced lung cancer whose tumors carry EGFR activating

mutations, first-line treatment with erlotinib nearly tripled

progression-free survival compared to a standard chemotherapy combination.


    Y.T. MA, UK


    Study reveals cancer-linked epigenetic effects of smoking (embargo: 9

October, 13:00 Milan time)


    For the first time, scientists have reported direct evidence that taking

up smoking results in epigenetic changes associated with the development of

cancer.


    U. Matulonis, US


    Investigational ovarian cancer drug shows promise against

platinum-resistant disease in Phase-II study (embargo: 9 October, 13:00 Milan

time)


To view this and other AsiaNet releases please visit http://www.asianetnews.net

    A drug being developed as a treatment for ovarian cancer has shown single

agent activity with durable disease control in some patients in a Phase-II

clinical trial.


    G. Long, AU


    Melanoma drug shrinks brain metastases in Phase-I/II study (embargo: 10

October, 11:00 Milan time)


    A new drug being developed to treat potentially deadly melanoma skin

cancers has shown a promising ability to shrink secondary tumors, known as

metastases, in the brain in patients with advanced forms of the disease.


    A. Palumbo, IT


    High response rate seen in Phase-III trial of chemotherapy, new drug and

stem cells in myeloma (embargo: 10 October, 12:30 Milan time)


    The first study of its kind comparing two different approaches to

treating newly diagnosed multiple myeloma has found that both treatments

achieved a positive response.


    M. Clavarezza, IT


    Most Italian breast cancer patients older, and diagnosed very early

(embargo: 10 October, 12:30 Milan time)


    A study of breast cancer in Italian women has found that more than 70% of

those affected by the disease are over the age of 50 years, and the disease

is identified before it has spread to the lymph nodes in more than 60% of

cases.


    H.A. Azim, BE


    Study finds breast-feeding safe for women after breast cancer treatment

(embargo: 10 October, 12:30 Milan time)


    Women who have survived breast cancer should not be denied the

opportunity to breast-feed their children. There is no evidence that

breastfeeding is dangerous for mother or child after breast cancer treatment.


    K.M. Tveit, NO


    Cetuximab adds no benefit to chemotherapy in first-line treatment of

metastatic colorectal cancer - New Phase-III data (embargo: 10 October, 13:30

Milan time)


    Adding the targeted drug cetuximab to a three-drug chemotherapy regimen

for first-line treatment of metastatic colorectal cancer does not improve

response rate, progression-free survival or overall survival.


    A. Gennari, IT


    Prolonging first-line chemotherapy improves outcomes for patients with

metastatic breast cancer (embargo: 10 October, 15:30 Milan time)


    Patients with metastatic breast cancer live longer on average if their

chemotherapy is continued after their cancer is brought under control, a new

meta-analysis shows.


    J. O'Shaughnessy, US


    Iniparib extends overall survival in metastatic triple-negative breast

To view this and other AsiaNet releases please visit http://www.asianetnews.net

cancer: final Phase-II results (embargo: 10 October, 15:30 Milan time)


    Women with an aggressive subtype of metastatic breast cancer appear to

live longer when treated with iniparib plus chemotherapy, compared to

chemotherapy alone, the results of a randomized Phase-II trial show.


    M. Pavel, DE


    Phase-III study shows everolimus delays tumor progression in

hard-to-treat neuroendocrine tumors (embargo: 11 October, 10:30 Milan time)


    The results of a large Phase-III clinical trial have shown that the drug

everolimus delays tumor progression in patients with a hard-to-treat group of

rare cancers that affect particular hormone-producing cells.


    B. Koczwara, AU


    Fertility concerns of cancer survivors inadequately addressed, study

finds (embargo: 11 October, 12:30 Milan time)


    Many cancer survivors experience changes in sexual function that leave

them feeling guilt and a longing for intimacy. The researchers say that these

sexuality and fertility concerns are often not adequately addressed by

doctors.


    Y. Loriot, FR


    Sexual issues a major concern for cancer patients taking new targeted

drugs (embargo: 11 October, 12:30 Milan time)


    New drugs that target specific molecular mechanisms of cancer have

improved the treatment of cancer patients in recent years, but those benefits

may come with a cost to the patient's sex life, researchers have found.


    B. You, FR


    Early cancer drug trials flawed by inconsistencies in prohibited drug

lists, study finds (embargo: 11 October, 12:30 Milan time)


    Substantial inconsistencies in a basic aspect of the way Phase-I and

Phase-II cancer clinical trials are designed. Researchers report finding

unexpectedly large differences in the lists of drugs that trial designers say

participants should not be given to avoid potentially dangerous drug-drug

interactions.


    T. Mok, CN


    New Phase-II study shows first-line promise of lung cancer drug PF-299

(embargo: 11 October, 13:15 Milan time)


    A new-generation lung cancer drug has shown an impressive ability to

prevent disease progression when administered as a first-line treatment in

patients with advanced disease.


    A. Necchi, IT


    Pazopanib shows promise in Phase-II trial for relapsed/refractory

urothelial cancer (embargo: 11 October, 13:30 Milan time)


    An ongoing Phase-II trial investigating a new, targeted therapy for

metastatic urothelial cancer has generated promising early results.


    J. Vermorken, NL

To view this and other AsiaNet releases please visit http://www.asianetnews.net


    Panitumumab fails to add overall survival benefit in recurrent/metastatic

head and neck cancer: full Phase-III results (embargo: 11 October, 13:30

Milan time)


    Adding the monoclonal anti-EGFR antibody panitumumab to chemotherapy did

not significantly improve overall survival for patients with recurrent and/or

metastatic head and neck cancer, according to Phase-III trial results.


    J. Baselga, US


    Adding cetuximab to chemotherapy doubles response rate in hard-to-treat

breast cancer (embargo: 11 October, 15:00 Milan time)


    For the first time researchers have proven that targeting the epidermal

growth factor receptor can provide substantial clinical benefit for women

with hard-to-treat "triple negative" breast cancer.


    E. Perez, US


    New type of targeted therapy shows promise as first-line therapy for

HER2-positive metastatic breast cancer (embargo: 11 October, 15:00 Milan

time)


    A new type of breast cancer treatment has shown encouraging activity as a

first-line therapy in HER2-positive metastatic disease.


    J. De Bono, UK


    Abiraterone acetate improves survival in metastatic castration-resistant

prostate cancer: Phase-III results (embargo: 11 October, 15:00 Milan time)


    Patients with metastatic castration-resistant prostate cancer who have

progressed after chemotherapy live significantly longer if treated with the

drug abiraterone acetate compared to placebo, the results of a large

Phase-III clinical trial confirm.


    C.H. Yang, TW


    Final results from landmark trial confirm survival benefits of EGFR

mutations in lung cancer (embargo: 11 October, 15:00 Milan time)


    Mature results from a landmark Phase-III trial have confirmed that

patients with EGFR mutation-positive advanced non-small cell lung cancer have

better overall survival when treated with gefitinib or chemotherapy than

patients whose tumors do not carry such mutations.


    V. Miller, US


    Afatinib benefits lung cancer patients whose cancer progressed after

treatment with EGFR inhibitors (embargo: 11 October, 15:00 Milan time)


    Lung cancer patients who have already been treated with the EGFR

inhibitors erlotinib or gefitinib seem to gain further benefits in terms of

progression-free survival and tumor shrinkage when treated with the new drug

afatinib, the results of a Phase-IIb/III trial show.


    T. Perren, UK


    Promising early results suggest bevacizumab adds survival benefit in

newly diagnosed ovarian cancer (embargo: 11 October, 15:00 Milan time)


    Early results from a large Phase-III trial suggest that adding

To view this and other AsiaNet releases please visit http://www.asianetnews.net

bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer

reduces the risk of disease progression during the first year of treatment.


    Embargo Policy


    All information presented at the 35th ESMO Congress is embargoed until 

the start of the session during which the abstract is presented. Journalists 

are required to observe embargoes as indicated.


    Appointments for media representatives


    Full details available at http://www.esmo.org/newsroom/events


    Friday, 8 October 2010, 12:00-13:00


    Opening Press Conference


    Latest available data on the global cancer burden; main topics to be

presented during the Congress, including the most recent advances in the

treatment of cancer; Congress statistics and highlights for members of the

media will be offered to attending journalists helping them to make their way

through what will be a very exciting meeting, thanks to a top-quality

program.


    

    - Prof. David J. Kerr, ESMO President


    - Prof. Rolf A. Stahel, ESMO2010 Scientific Chair


    - Prof. Fortunato Ciardiello, ESMO2010 Press Officer


    Saturday, 9 October 2010, 8:15-9:00


    Press Briefing Day 1


    Advanced breast cancer, Chest tumors, Palliative Care


    Saturday, 9 October 2010, 12:00-12:45


    Press Conference - The battle against rare cancers in Europe


    More clinical trials for rare cancers are needed in Europe. Current lack

of information, late diagnosis or misdiagnosis and practical obstacles to

research, treatment and care will be discussed.


    Sunday, 10 October 2010, 8:15-9:00


    Press Briefing Day 2


    Early and advanced breast cancer


    Sunday, 10 October 2010, 12:15-13:00


    Press Conference - Cancer patient long-term rehabilitation: body and

beyond


    Welfare and healthcare, public and private employment, equal treatment,

communications and awareness will be discussed (at national and European

level) to raise interest in cancer patient issues that are too often

underestimated.


    Monday, 11 October 2010, 8:15-9:00


To view this and other AsiaNet releases please visit http://www.asianetnews.net

    Press Briefing Day 3

Advanced breast cancer, Chest tumors, Gynecological cancers, Genitourinary

tumors


    Tuesday, 12 October 2010, 8:15-9:00


    Wrap-up


    Your opportunity to ask any unanswered questions

Closing comments by the President on the most important congress scientific

presentations Updated event figures


    General information


    

    - The full conference program is available at



    - All press events will be held in Room Asia, Press Center, Mezzanine

    Bridge but can be followed also remotely via toll-free dial-in:


    - Australia: 1-800-00-59-03

    - Belgium: 0800-39-244

    - Canada: (1)866-416-25-55

   

-

China North: 10-800-712-18-94

    - China South: 10-800-120-18-94

    - France: 0800-946-502

    - Italy: 800-136-706

    - Japan: 00531-12-12-66

    - Netherlands: 0800-949-45-17

    - Spain: 900-803-963

    - Switzerland: 800-24-67-87-00

    - UK: 800-3681-054

    - USA: (1)866-291-41-66

    - Other numbers available upon request

    - Interested journalists are kindly requested to notify us asap

    if they intend to use the remote dial-in



    - You can contact the ESMO Press Office at media@esmo.org to pre-book

    your interviews both in presence and remotely. Experts in various 

    oncology fields will be available in the ESMO Media Ambassador Corner 

    in the Press Center for interviews every day.


    Media registration


    On-site registration is possible at the Press Registration Desk. You will

be asked for your press card and a letter of assignment.


    

    Contact:

    Vanessa Pavinato

    Mobile: +41-79-935-60-73

    E-Mail: media@esmo.org

    Congress Press Office tel.: +39-02-4342-3649 (as of Thursday, 7 October)


    SOURCE: European Society for Medical Oncology (ESMO)


Translations:








news articles logo NEWS ARTICLES
Contact News Articles |Remove this article